The importance of an independent validation cohort for metabolomics biomarker studies

Trezzi, Jean-Pierre; Hiller, Karsten; Mollenhauer, Brit

doi:10.1002/mds.27374

Cited by 4 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described above, PD is biologically complex, a result of many intersecting processes that vary from person to person. Blood and cerebrospinal fluid parameters associated with PD show high inter-individual heterogeneity, requiring combinations of multiple markers to optimize diagnostic accuracy [ 24 ]. Variable co-pathology adds to the heterogeneity [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations

Mestre

Fereshtehnejad

Berg

et al. 2021

JPD

Self Cite

View full text Add to dashboard Cite

Background: In Parkinson's disease (PD), there is heterogeneity in the clinical presentation and underlying biology. Research on PD subtypes aims to understand this heterogeneity with potential contribution for the knowledge of disease pathophysiology, natural history and therapeutic development. There have been many studies of PD subtypes but their impact remains unclear with limited application in research or clinical practice. Objective: To critically evaluate PD subtyping systems. Methods: We conducted a systematic review of PD subtypes, assessing the characteristics of the studies reporting a subtyping system for the first time. We completed a critical appraisal of their methodologic quality and clinical applicability using standardized checklists. Results: We included 38 studies. The majority were cross-sectional (n = 26, 68.4%), used a data-driven approach, and nonclinical biomarkers were rarely used (n = 5, 13.1%). Motor characteristics were the domain most commonly reported to differentiate PD subtypes. Most of the studies did not achieve the top rating across items of a Methodologic Quality checklist. In a Clinical Applicability Checklist, the clinical importance of differences between subtypes, potential treatment implications and applicability to the general population were rated poorly, and subtype stability over time and prognostic value were largely unknown. Conclusion: Subtyping studies undertaken to date have significant methodologic shortcomings and most have questionable clinical applicability and unknown biological relevance. The clinical and biological signature of PD may be unique to the individual, rendering PD resistant to meaningful cluster solutions. New approaches that acknowledge the individual-level heterogeneity and that are more aligned with personalized medicine are needed.

show abstract

Section: Discussionmentioning

confidence: 99%